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In the human body, billions of cells die by apoptosis every day. The subsequent clearance 
of apoptotic cells by phagocytosis is normally efficient enough to prevent secondary 
necrosis and the consequent release of cell contents that would induce inflammation and 
trigger autoimmunity. In addition, apoptotic cells generally induce an anti-inflammatory 
response, thus removal of apoptotic cells is usually immunologically silent. Since the 
first discovery that uptake of apoptotic cells leads to transforming growth factor (TGF)-β 
and interleukin (IL)-10 release by engulfing macrophages, numerous anti-inflammatory 
mechanisms triggered by apoptotic cells have been discovered, including release of anti- 
inflammatory molecules from the apoptotic cells, triggering immediate anti-inflammatory 
signaling pathways by apoptotic cell surface molecules via phagocyte receptors, activat-
ing phagocyte nuclear receptors following uptake and inducing the production of anti-in-
flammatory soluble mediators by phagocytes that may act via paracrine or autocrine 
mechanisms to amplify and preserve the anti-inflammatory state. Here, we summarize 
our present knowledge about how these anti-inflammatory mechanisms operate during 
the clearance of apoptotic cells.
Keywords: apoptotic cell, phagocytosis, anti-inflammatory, pro-resolving lipid mediators, phosphatidylserine
iNTRODUCTiON
Timed initiation of apoptotic type of cell death followed by prompt removal carried out by profes-
sional engulfers or by non-professional neighboring cells plays a central role in the maintenance of 
tissue homeostasis. Every day billions of our cells die and get removed without inducing inflamma-
tion and autoimmunity (1). And even when inflammation is induced, efficient clearance of apoptotic 
neutrophils by engulfing macrophages during the inflammatory response is a determining event 
in initiating resolution of inflammation and contributes to the tissue repair processes following 
injury (2–5).
To initiate effective clearance, apoptotic cells attract engulfing cells by secreting various chemotactic 
signals, such as CX3CL1/fractalkine (6), lysophosphatidylcholine (7), sphingosine-1-phosphate (8), 
thrombospondin-1 (TSP-1) (9), ATP and UTP (10), endothelial monocyte-activating polypeptide II 
(11), monocyte chemoattractant protein-1 (12), cleaved human tyrosyl-tRNA synthetase (13), or the 
S19 ribosomal protein cross-linked dimer (14). Upon approaching the dying cells, engulfing cells must 
make a distinction between dead and living cells, and they act so by recognizing apoptotic cell-asso-
ciated molecular patterns (ACAMPs) displayed on the cell surface of apoptotic cells (15). Most of the 
ACAMPs are phagocytosis initiating “eat me” signals, which are able to trigger receptors on phagocytes 
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either directly or via bridging molecules. Phosphatidylserine 
(PS) on the outer leaflet of the cell membrane is the most uni-
versally seen “eat me” signal appearing in apoptotic cells (16). 
Stabilin-2, the macrophage receptor T-cell immunoglobulin- 
and mucin-domain-containing molecule (Tim4), and brain-
specific angiogenesis inhibitor 1 have the ability to directly 
engage PS on dying cells (17–19), other receptors, such as Mer 
tyrosine kinase (MerTk) (20), scavenger receptor SCARF1 (21), 
or integrin αv/β3/β5 either with the CD36 (22) or with the trans-
glutaminase 2 (TG2) coreceptors (23) require bridging molecules 
for PS binding. While for MerTk Gas6 and Protein S serve as 
bridging molecules (24, 25), TSP-1 and milk-fat globulin-E8 play 
a similar role for the integrin αv/β3/CD36 and integrin αv/β3/
TG2 receptor complexes, respectively (22, 26, 27). In the case of 
apoptotic neutrophils, however, the matricellular protein CCN1 
bridges PS to the αv/β3 and αv/β5 integrins of macrophages (28).
Besides the PS-recognizing bridging molecules, additional 
bridging molecules also contribute to the phagocytosis of apop-
totic cells. Thus, serum protein C1q links Annexin A2 and A5 on 
the apoptotic cells (29) to both the SCARF1 scavenger receptor 
and to the calreticulin-associated CD91 receptor on macrophages 
(20, 30, 31). Apoptotic neutrophils, T cells, and human mesangial 
cells release annexin I (32), and annexin I enhances phagocytosis 
of apoptotic cells via a mechanism that requires FPR2/ALX 
receptor and its internalization (33).
Interestingly, simultaneous triggering of all these phagocytic 
receptors seems to result in the activation of only two evolution-
ary conserved signaling pathways both leading to the activation of 
Rac1, a small GTPase that regulates cytoskeletal rearrangements 
required for the phagocytosis process (34).
Uptake of apoptotic cells delivers excess materials to the phago-
cytes, which is degraded after the newly formed phagosome fuses 
with the lysosomes (35, 36). However, for full protein degradation 
besides the lysosomal cathepsins (35), the proteosomal pathway 
also has to be activated (37). In addition, to successfully metabo-
lize lipids originated from the apoptotic cells, phagocytes also 
require the lipid metabolism organizing function of their lipid 
sensing nuclear receptors, the liver X receptors (LXRs), and the 
perixosome proliferator-activated receptors (PPARs) (38). LXRs 
and PPARs are ligand-regulated transcription factors belonging 
to the nuclear receptor family. They function in the form of heter-
odimers with the retinoid X receptors (RXRs) (39). The unligated 
LXRs and PPARs are located on their respective DNA response 
elements and recruit co-repressor molecules that repress the tran-
scription of their target genes. Binding of their ligand, however, 
induces such a conformational change in their structure that 
results in the exchange of co-repressors for co-activators, and in 
the consequent start of transcription. In addition, ligated LXR 
and PPAR heterodimers are also capable of transrepressing genes, 
the transcription of which would otherwise be initiated by other 
transcription factors (39).
The ligands of LXRs are sterol metabolites (40, 41), while for 
PPARs are unsaturated fatty acids, eicosanoids, and derivatives 
of linoleic acid (42). Metabolically, the main function of LXRs is 
to regulate whole body sterol metabolism (38). Since, in mam-
malians, sterols cannot be degraded; in macrophages, following 
the degradation of apoptotic cells, activated LXRs induce the 
expression of cholesterol efflux transporters ABCG1 and ABCA1, 
Apo lipoproteins ApoC and ApoE, and the lipoprotein remodeling 
enzyme PLTP (43) promoting this way the efflux of apoptotic cell-
derived sterols onto serum apolipoproteins and their transport to 
the liver, from where sterols will be redistributed again. PPARs, 
on the other hand, are involved in nearly every facet of fatty 
acid metabolism (44). Thus, PPARγ controls the expression of 
genes involved in lipid metabolism (43), while PPARδ controls 
the macrophage energy homeostasis by regulating the expression 
of genes involved β-oxidation, mitochondrial respiration, and 
thermogenesis (45).
While engulfment of a number of pathogenic targets induces a 
pro-inflammatory program in macrophages, uptake of apoptotic 
cells initiates their transition into an anti-inflammatory phenotype. 
Furthermore, apoptotic cells are capable of actively inhibiting the 
inflammatory program. For example, the inflammatory response 
induced by lipopolysaccharide (LPS), a component of the cell wall 
of Gram-negative bacteria, is strongly attenuated by preincuba-
tion of macrophages with apoptotic cells (46–48). First, after the 
exposure to apoptotic cells, an immediate-early inhibition of 
macrophage pro-inflammatory cytokine gene transcription can 
be detected (46, 47), subsequently, both nuclear receptors (38) are 
activated and, as it was first recognized, soluble mediators, such 
as transforming growth factor (TGF)-β and interleukin (IL)-10, 
are released (48). These mediators act via paracrine or autocrine 
mechanisms to strengthen and maintain the anti-inflammatory 
state (47, 48). The aim of this review is to highlight how these 
efferocytotic processes are coupled to the anti-inflammatory 
mechanisms provoked simultaneously by apoptotic cells, since 
efficient apoptotic cell removal and induction of immunologic 
tolerance by apoptotic cells are the two crucial mechanisms that 
prevent chronic inflammation and autoimmunity (49).
APOPTOSiS iS AN iMMUNOLOGiCALLY 
SiLeNT FORM OF CeLL DeATH
Increasing evidence indicates that the caspase-dependent apop-
tosis is unique in a sense that it is an immunologically silent 
form of cell death (50). Whereas necrotic cells typically provoke 
inflammation, apoptotic cells generally do not. What is more, 
even if apoptotic cells enter secondary necrosis and are leaking 
their cellular contents, they retain this anti-inflammatory state, 
in contrast to cells that have entered necrosis directly (51, 52). 
This suggests that significant alterations to cellular composition 
must occur during apoptosis to diminish the activity of danger-
associated molecules (DAMPs), and even if these are accidentally 
released, their pro-inflammatory activity is destroyed. There 
are several examples recently discovered that underline this 
assumption.
Genomic DNA is considered to be an important DAMP capable 
of initiating dendritic cell (DC) maturation and the initiation of 
immune responses to coadministered antigens (53). Conversely, 
hydrolysis of DNA with endonucleases strongly attenuates its 
immune-activating properties (54). In apoptotic cells, genomic 
DNA undergoes extensive hydrolysis to small ~200 bp fragments 
due to the actions of a caspase-activated DNAse (55). If DNA 
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cannot be degraded by either apoptotic or phagocytic endonucle-
ases, autoimmunity develops (55), which is related to incompletely 
digested DNA persisting in macrophages leading to the activation 
of the RIG-I/IRF-3 pathway which senses cytoplasmic DNA frag-
ments (56). In addition to the caspase-dependent degradation of 
genomic DNA, activated caspase-8 itself also interferes with the 
RIG-I/IRF-3 pathway by proteolytically inactivating RIP kinase 
1, a key signaling component of the RIG-I complex, and thereby 
attenuating expression of IRF-3-inducible genes that include 
interferons and other inflammatory factors (57). Apoptotic 
caspases, via interfering with the cGAS/STING pathway, prevent 
the induction of type I interferons also by mitochondrial DNA, 
which can be released into the cytosol during apoptosis following 
permeabilization of the mitochondrial outer membrane (58).
High mobility group 1 (HMGB1) is another well-known 
DAMP. It functions in the cell nucleus as an architectural 
chromatin-binding factor via bending DNA and facilitating 
this way the buildup of protein complexes on specific DNA 
sequences. But it associates only loosely with the DNA, and 
can be passively released by necrotic or damaged cells (59). In 
apoptotic cells, however, HMGB1 remains bound firmly to 
chromatin due to the generalized hypoacetylation of histones, 
another caspase-dependent event (59). Furthermore, caspases 
also inactivate HMGB1 indirectly via cleaving the mitochondrial 
protein p75NDUF. This event triggers a burst of reactive oxygen 
leading to oxidation of a critical cysteine residue on HMGB1 that 
neutralizes its pro-inflammatory activity (60). And finally, IL-33, 
a recently discovered alarmin, is also cleaved by caspases loosing 
this way its DAMP activity (61).
APOPTOTiC CeLLS ReLeASe ANTi-
iNFLAMMATORY MOLeCULeS
Apoptotic cells not only fail to be strongly immunogenic but 
were found to release various anti-inflammatory molecules as 
well. Thus, T cells express TGF-β, and release it during apoptosis 
(62). TGF-β is a potent anti-inflammatory cytokine (63). Its anti-
inflammatory effects are reflected in the observation that loss of 
TGF-β1 in mice leads to wasting syndrome accompanied by a 
multifocal, mixed inflammatory cell response and tissue necrosis, 
resulting in organ failure and death (64, 65). Both the initiation 
and resolution of general inflammatory responses involve TGF-β1. 
Thus, TGF-β1 stimulates monocyte migration and growth factor 
production (66). But after initiation of an inflammatory response, 
it also exhibits potent anti-inflammatory effects, including inhibi-
tion of neutrophil and T-lymphocyte adhesion to endothelium 
(67), downregulation of macrophages (66, 68), and antagonism 
of tumor necrosis factor-α (TNF-α) function (68). TGF-β is 
crucial also in the initiation of differentiation of the regulatory 
T cells (69), which play a key role in preventing the development 
of autoimmunity (70). TGF-β plays such an essential role in the 
initiation of regulatory T  cell differentiation that prior to the 
initiation of thymocyte apoptosis no Treg cells can be detected 
in the thymus (71).
Apoptotic cells can also release IL-10 (72). IL-10, together with 
TGF-β, induces an immune suppressive response by promoting 
regulatory T cell formation and by affecting their function (73).
Annexin I, which is released by apoptotic cells and promotes 
efferocytosis (32, 33), was also found to significantly attenuate IL-6 
signaling and the release of TNF-α from endotoxin-challenged 
monocytes by activating annexin A1 receptors of the formyl 
peptide receptor family and the consequent JAK/STAT/SOCS 
signaling (74). And, finally, apoptotic cells were found to release 
lactoferrin that inhibits the migration of neutrophil granulocytes 
and eosinophils toward the chemotactic signals released by apop-
totic cells (75, 76). As a result, apoptotic cells induce only migra-
tion of macrophages, but other classes of professional phagocytes 
are not recruited by the apoptotic cells (76).
Increasing evidence indicate that several chemotactic signals 
released from the apoptotic cells can also serve as anti-inflam-
matory molecules. Thus, TSP-1 functions as a major activator 
of TGF-β1 (77) which is secreted to the extracellular matrix in 
an inactive form by being in non-covalent association with the 
latency-associated peptide (78). First, TSP-1 releases TGF-β1 
from its latent form via interacting with the N-terminal region 
of latency-associated peptide, then it binds the mature TGF-β1. 
This interaction induces such a conformational change in the 
structure of TGF-β1 (79), which allows its binding to its recep-
tor. Furthermore, TSP-1 or its protease-cleaved derivative can 
also bind to immature DCs (iDCs) and induce their tolerogenic 
state (80). Fractalkine was also shown to act as an inhibitor of 
LPS-induced TNF-α production by microglia cells (81), while 
lysophosphatidylcholine was reported to interfere with the 
LPS-induced NO and pro-inflammatory cytokine production by 
macrophages (82).
Once released from the apoptotic cells via a caspase-regulated 
pannexin channel (83), ATP is fast degraded to AMP very often 
on the surface of apoptotic cells (84) and then to adenosine by 
the cell surface 5′ nucleotidase of engulfing macrophages (85, 86). 
Adenosine then triggers macrophage adenosine A2A receptors 
(A2ARs) to suppress the NO-dependent formation of neutrophil 
migration factors, such as macrophage inflammatory protein-2, 
via activating the adenylate cyclase/protein kinase A pathway 
(86). Interestingly, both adenosine A2A and A3 (A3R) receptors 
are expressed by macrophages, and while A2ARs inhibit, A3Rs 
promote the release of neutrophil migration factors by engulfing 
macrophages (87). However, while A2AR expression increases 
(86), A3R is downregulated during the course of efferocytosis 
(87) potentiating and maintaining this way the anti-inflammatory 
effects of adenosine. In addition, adenosine, by triggering 
adenosine A3R, contributes also to the chemotactic navigation 
of macrophages toward the apoptotic cells driven by apoptotic 
cell-derived chemotactic signals, thus facilitates the fast clearance 
of apoptotic cells (88). As a result, downregulation of A3R during 
clearance prolongs their presence around the apoptotic cells.
In an inflammatory milieu, adenosine strongly suppresses also 
the LPS-induced pro-inflammatory cytokine formation of mono-
cytes and macrophages by activating A2ARs (89). In monocytes 
adenosine increases the expression of the Nr4A orphan nuclear 
receptor which then inhibits the transcriptional activity of nuclear 
factor-κB (NF-κB) known to play a determining role in initiat-
ing the transcription of numerous pro-inflammatory cytokines 
(90). The adenosine-triggered adenylate cyclase pathway in 
LPS-activated macrophages, on the other hand, upregulates the 
4Szondy et al. Inhibition of Inflammation by Apoptotic Cells
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 909
expression of dual-specific phosphatase 1 that interferes with the 
activation of LPS-activated MAP kinases (91).
APOPTOTiC CeLLS TRiGGeR ANTi-
iNFLAMMATORY SiGNALiNG PATHwAYS 
BY ACTivATiNG CeLL SURFACe 
PHAGOCYTOSiS ReCePTORS ON THe 
PHAGOCYTe
Soon after it was discovered that PS recognition plays a central 
role in the uptake of apoptotic cells (92), it was also discovered 
that PS recognition in macrophages mediates also some of the 
anti-inflammatory responses observed during the uptake of 
apoptotic cells (93). This was proven by the observation that 
several anti-inflammatory responses provoked by apoptotic cells 
can be prevented by administration of annexin V, a naturally 
occurring PS binding protein (92), or are not induced by cells that 
do not express PS during apoptosis. In addition, in the induction 
of these anti-inflammatory effects, apoptotic cells can be replaced 
by PS liposomes (94). Some of the PS-induced anti-inflammatory 
responses are direct and can be detected as immediate inhibition 
of NF-κB transcriptional activity (46). Some others appear later, 
such as upregulation of the zinc finger nuclear factor, named GC 
binding protein (GC-BP) (95), or that of the Nr4a1 transcrip-
tion factor (96). By binding to its promoter, GC-BP selectively 
inhibits IL-12 p35 gene transcription (95), while Nr4a1inhibits 
both NF-κB transcriptional activity and the induction of IL-12 
(96). The induction of these transcription factors, however, might 
be macrophage type specific, because Nr4a1 induction is seen in 
peritoneal, but not in bone marrow-derived macrophages (96).
In addition to these intracellular anti-inflammatory effects, PS 
is also responsible for triggering TGF-β1 secretion from engulf-
ing macrophages. Thus, apoptotic PLB-985 cells that are unable 
to express PS during apoptosis, fail to trigger TGF-β1 production, 
while PS directly transferred onto the PLB-985 cell surface mem-
branes or PS liposomes can restore the secretion of TGF-β1 (94).
Since PS is recognized by a number of phagocytic receptors 
and opsonins that span a wide range of gene families, it is very 
likely that they induce immune suppression and tolerance via 
overlapping and non-overlapping mechanisms. Among the PS 
receptors, TIM-4 is not expected to transmit anti-inflammatory 
signals; since in the absence of a cytoplasmic tail, it alone cannot 
activate an intracellular signaling pathway (97). However, stabi-
lin-2 was shown to be involved in inducing TGF-β1 release from 
engulfing macrophages (18), while MerTk was found to have a 
direct anti-inflammatory activity that suppresses NF-κB (98). The 
anti-inflammatory action of MerTk is independent of its effect 
on efferocytosis and is related to a signal transduction pathway 
that prevents the LPS-induced phosphorylation of IκB kinase 
and the consequent degradation of IκB (98). Whether other 
phagocytosis receptors also participate in the induction of the 
anti-inflammatory response of macrophages is still under investi-
gation, but CD36 and αvβ3 receptors do not seem to participate in 
it (99). Interestingly, however, loss of both MerTk and TG2 leads 
to pro-inflammatory cytokine production during efferocytosis 
(100, 101). But the pro-inflammatory cytokine production in 
this latter case might be related not only to an improper integrin 
signaling for which TG2 is a cofactor but also to the fact that TG2 
is required for proper TGF-β activation by macrophages (102).
Phosphatidylserine receptors are expressed not only by 
macrophages but by other immune cells as well. As a result, 
apoptotic cells can transmit further immune silencing signals 
via activating PS receptors on those cells as well. For example, it 
has been shown that in the presence of apoptotic cells, iDCs do 
not induce expression of DC maturation-markers, such as MHC 
class-II, CD40, CD80, CD83, and CD86, even after challenge with 
CD40-signaling, monocyte-conditioned medium, LPS, or TNF-α  
(103–108). Furthermore, activation of PS receptors in human 
DCs by PS liposomes reduces their IL-12p70 secretion and the 
capacity to stimulate allogeneic T cell proliferation and to activate 
IFN-γ-producing CD4+ T cells (109). iDCs express MerTK, and 
activation of MerTK in iDCs triggers the phosphatidylinositol 
3-kinase signaling pathway, which inhibits NF-κB activation and 
the consequent DC maturation (110). As a result, iDCs, which 
do not express MerTk or are treated with phosphatidylinositol 
3-kinase inhibitors, do not respond to the immunosuppress-
ing effect of apoptotic cells on LPS-induced pro-inflammatory 
cytokine formation (111). DCs also express Axl, another member 
of the TAM receptor family. The basal expression of Axl in DCs is 
very low, but it is significantly upregulated following TLR engage-
ment. Axl, following activation, induces resolution of inflamma-
tion at the end of an inflammatory cycle (111). Ligation of the 
thrombospondin receptor CD36 also inhibits iDC maturation 
and function by suppressing the release of IL-12 and the secretion 
of high levels of IL-10 in response to DC-activation stimuli (105).
T  cells, on the other hand, express the PS receptor TIM-3, 
another member of the TIM receptor family. In T cells, TIM-3, 
following PS exposure, transmits an immunosuppressive signal 
by sequestering lck, a critical tyrosine kinase participating in 
T cell receptor-mediated signal transduction (112).
In addition to PS, late apoptotic neutrophils were shown to 
express also pentraxin 3 (PTX3) in their membranes (113). PTX3 
was shown not only to enhance their phagocytic removal during 
inflammation (113) but also to induce the expression of CD169 in 
macrophages (114), a molecule that interferes with the develop-
ment of an autoimmune response (115).
NUCLeAR ReCePTORS ACTiveLY 
SUPPReSS PRO-iNFLAMMATORY 
CYTOKiNe FORMATiON BY iNHiBiTiNG 
NF-κB
Once apoptotic cells are taken up, they have to be fast metabo-
lized by macrophages in order to ingest further apoptotic cells. 
Uptake of high amount of extracellular material might induce 
a metabolic stress in the engulfing macrophages, and engulf-
ing macrophages respond to it in many ways by altering their 
metabolism. Interestingly, these metabolic adaptors also seem to 
contribute to the immune silencing processes as well. Thus, the 
amino acid metabolic-stress sensing protein kinase GCN2 was 
implicated to participate in the signaling pathways that lead to 
tolerance (116).
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Similarly, the lipid sensing nuclear receptors that func-
tion during engulfment as transcriptional regulators of lipid 
metabolic processes also interfere with inflammatory processes, 
such as those initiated by TLR signaling in macrophages. As it 
was reviewed by Kidani et  al. (38), under non-inflammatory 
conditions, NF-κB target genes are kept in an inhibited state 
by co-repressor complexes associated with their promoters. 
As a response to inflammatory signaling, proteins of these co-
repressor complexes become ubiquitinated and subsequently 
degraded by the 19S proteasome. At the same time, NF-κB 
activated simultaneously by the inflammatory signals trans-
locates into the nucleus, binds to promoters of inflammatory 
genes, and induces their expression. Ligation of PPARγ during 
efferocytosis prevents NF-κB-regulated gene expression by sus-
taining co-repressor binding on the promoters of NF-κB target 
genes. This is related to the fact that ligand binding to PPARγ 
induces conformational changes that allows for SUMOylation of 
its ligand-binding domain. SUMOylated PPARγ, subsequently, 
binds to the co-repressor complex and prevents its degradation 
by the 19S proteasome, thereby sustaining the suppressed state. 
LXR-mediated transrepression of NF-κB target genes operates via 
similar mechanisms involving SUMOylation of LXR by HDAC4, 
SUMO2, or SUMO3 as the E3-ligase (38).
Ligated PPARδ also interferes with the NF-κB transcription, 
but it operates through a different mechanism. BCL-6 is an evo-
lutionarily conserved zinc finger transcription factor that acts as a 
sequence-specific repressor of transcription. Unliganded PPARδ 
sequestrates BCL-6 away from the promoters of inflammatory 
genes; while following ligand binding PPARδ releases BCL-6 
leading to suppression of inflammatory gene transcription (117).
Ligated nuclear receptors are also anti-inflammatory because 
during efferocytosis they upregulate the expression of various 
phagocytic receptors, thus, enhance the clearance capacity of 
macrophages (118–122). The upregulation of some phagocytic 
genes by these receptors, such as MerTk by LXR, is direct, while 
that of others is mediated via retinoic acid receptor (RAR)-α (121, 
122). In engulfing macrophages, activation of all lipid sensing 
receptors leads to the upregulation of retinaldehyde dehydroge-
nase expression, an enzyme responsible for retinoic acid synthesis 
(123). Retinoic acids, ligands for the RAR and RXR receptors, 
then can promote both the transcriptional activity of lipid sensing 
nuclear receptors and trigger that of the RARs (122). In addition, 
LXRs are also involved in the induction of the synthesis of poly-
unsaturated fatty acids, which are precursors for the production 
of pro-resolving lipid mediators (124). And finally, ligated nuclear 
receptors are also responsible for the upregulation of A2ARs that 
mediate the anti-inflammatory effect of adenosine (86).
Besides the lipid sensing nuclear receptors, the orphan 
nuclear receptor Nr4a1 has also been implicated to act as an 
anti-inflammatory molecule during efferocytosis (96). Nr4a1 
seems to interfere with the TLR signaling pathway at two levels: 
(1) it can interact with TRAF6, a central adaptor molecule in 
the TLR signaling pathway. The interaction affects TRAF6 auto-
ubiquitination leading to the suppression of NF-κB activation 
and to that of the subsequent transcription of pro-inflammatory 
cytokines (125). (2) It directly associates with the p65 subunit of 
NF-κB and prevents its binding to the κB promoter. However, 
this latter effect of Nr4a1 might be suspended by its LPS-induced 
p38α phosphorylation (126).
MACROPHAGeS ReSPOND TO 
APOPTOTiC CeLL UPTAKe BY 
ReLeASiNG ANTi-iNFLAMMATORY OR 
PRO-ReSOLviNG MOLeCULeS
Since the first discovery that macrophages engulfing apoptotic cells 
release TGF-β and IL-10 (47, 48), numerous other anti-inflammatory 
molecules have been described to be released by engulfing mac-
rophages. Many of these anti-inflammatory molecules are lipid 
mediators, such as PGE2, PGF1α, LXA4, or PAF, the synthesis of which 
is interestingly dependent on TGF-β (127). TGF-β at the same time 
inhibits the synthesis of pro-inflammatory lipid mediators. While in 
the case of TGF-β, it was found that activation of PS receptors can 
regulate its production (94), the regulation of IL-10 synthesis by mac-
rophages engulfing apoptotic cells was not studied in detail. Annexin 1, 
however, is a known inducer of it in macrophages (128).
Retinoids produced during engulfment to enhance efferocytosis 
(122, 123) can also be released into the surrounding environment 
and contribute to the TGF-β-induced development of regulatory 
T cells. They act so by stabilizing TGF-β-induced Foxp3 expression 
under inflammatory conditions via inhibiting DNA methylation, 
which otherwise would lead to the silencing of the Foxp3 gene 
(129). Since regulatory T  cells play a central role in preventing 
autoimmunity, release of TGF-β and retinoids by engulfing mac-
rophages strongly contributes to the prevention of an autoimmune 
response build up following engulfment of apoptotic cells (70).
In addition to producing anti-inflammatory mediators, engulf-
ing macrophages converted from M1 pro-inflammatory mac-
rophages to M2 CD11blow macrophages (130) during inflammation 
are also capable of producing pro-resolving lipid mediators, such 
as resolvins, protectins, and maresin (131–133). These molecules 
are synthetized from ω-3 fatty acids via the 12/15-lipoxygenase 
pathway. Pro-resolving mediators are stimulators of resolution of 
inflammation. Each facilitates cessation of neutrophil transmigra-
tion, microbial phagocytosis, and engulfment of apoptotic neutro-
phils. They also promote the formation of CD11blow macrophages, 
which in addition to producing pro-resolving lipid mediators, 
also contribute to the termination of efferocytosis and emigration 
to lymphoid organs (130) required for the proper termination 
of the inflammatory program. The conversion to pro-resolving 
macrophages is also facilitated by the atypical chemokine receptor 
D6 expressed on the surface of apoptotic neutrophils (134) and by 
the apoptotic cell uptake itself (135).
And, finally, apoptotic cells also modulate the function of 
immature iDCs in a way that they force them to secrete molecules 
which inhibit T cell function. For example, apoptotic cells induce 
in iDCs the secretion of interferon-γ that upregulates via autocrine 
and paracrine mechanisms their indoleamine 2,3-dioxygenase 
activity leading to the degradation of tryptophan into metabolites 
that inhibit T cell function (136). Apoptotic cells also induce the 
release of large amounts of nitric oxide from iDCs that impairs 
the T cell response (137). At the same time uptake of apoptotic 
cells by iDCs triggers TGF-β production, which also strongly 
FiGURe 1 | Mechanisms of the anti-inflammatory effects of apoptotic cells. 
Apoptotic cells release various anti-inflammatory molecules, such as 
transforming growth factor (TGF)-β, interleukin (IL)-10, annexin I, 
thrombospondin-1 (TSP-1), fractalkine to inhibit pro-inflammatory cytokine 
formation of phagocytes. Once released from the apoptotic cells via a 
caspase-regulated pannexin channel, ATP is fast degraded to adenosine by 
the cell surface 5′ nucleotidase of engulfing macrophages. Adenosine then 
triggers macrophage adenosine A2A receptors to suppress the NO-
dependent formation of neutrophil migration factors, or in an inflammatory 
milieu the lipopolysaccharide (LPS)-induced pro-inflammatory cytokine 
formation by phagocytes. Apoptotic cells express phosphatidylserine (PS), 
which activates various PS sensing phagocytic receptors. Many of these 
receptors initiate such intracellular signaling pathways that interfere with the 
pro-inflammatory cytokine formation of phagocytes. Following engulfment, 
the lipid content of the apoptotic cells activate the nuclear lipid sensing 
receptors [liver X receptors (LXRs) and perixosome proliferator-activated 
receptors (PPARs)], which in ligated form can also interfere with the 
NF-κB-driven pro-inflammatory cytokine formation. And, finally, engulfing 
macrophages release TGF-β, IL-10, and retinoids, which act in a paracrine or 
autocrine fashion to amplify and sustain the anti-inflammatory response and 
strongly contribute to the formation of the regulatory T cells to prevent the 
development of autoimmunity.
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contributes to the immunosuppressive effects of apoptotic cells 
in vivo (138). Interestingly, plasmacytoid DCs, which themselves 
cannot engulf apoptotic cells, can also initiate an apoptotic cell-
induced anti-inflammatory response. However, their response 
is dependent on engulfing macrophage-derived soluble factors, 
including TGF-β (139).
CONCLUDiNG ReMARKS
Apoptotic cell death is a determinant contributing factor to the 
cell turnover in most of the tissues. The silent removal of apop-
totic cells maintains tissue integrity under healthy conditions 
and its anti-inflammatory nature contributes to the resolution 
of inflammation (Figure  1). Since the initial discovery that 
apoptotic cells possess potent immune suppressing effects on 
phagocytes of the immune system, numerous laboratories have 
initiated successful apoptotic cell-based therapies to induce 
donor-specific immunosuppression in transplantation (140). 
Though similar strategies were successful in mouse autoim-
mune experimental models as well, where apoptotic cells 
were given at the time of triggering of the disease (141), they 
would very likely fail in the treatment in chronic inflammatory 
diseases. This assumption is based on the observation that the 
establishment and/or progression of an increasing number of 
chronic inflammatory diseases seem to be coupled to improper 
phagocytosis of apoptotic cells (142). If the removal of apoptotic 
cells is delayed, their cell content is released and induces tissue 
damage leading to long-term inflammation or even to autoim-
munity (143). During the past decade, we have understood 
that the development of chronic inflammation in these cases 
is related not only to the disturbed removal of dead cells but 
very likely also to the improper anti-inflammatory regulation 
that develops as a consequence of the improper clearance. Thus, 
enhancing efferocytosis and/or the related anti-inflammatory 
and pro-resolving mechanisms might provide a possibility in 
the treatment of those human chronic inflammatory diseases, in 
which impaired clearance of apoptotic cells appears as a driving 
or contributing force (49).
While the anti-inflammatory nature of apoptotic cell clearance 
is protective in healthy tissues, high PS expression of apoptotic 
tumor cells might promote tumor growth via suppressing immu-
nity (93). Indeed, increasing evidence indicate that systemic 
administration of annexin A5 or other PS ligands that cover PS 
and block PS-mediated apoptotic tumor cell signaling may slow 
down tumor progression via interfering with the immunosup-
pressive properties of apoptotic tumor cells and tumor-derived 
microvesicles (144, 145). Thus, it was suggested that in combina-
tion with radio- or chemotherapy, annexin A5 could be used 
as a natural adjuvant to increase the immunogenicity of dying 
tumor cells thereby promoting the development of an anti-tumor 
immune response (93, 146).
And, finally, it is worth to note that though apoptotic cells are 
generally anti-inflammatory, cancer cells undergoing apoptosis 
in response to specific anticancer therapies can be immunogenic, 
if they emit precise DAMPs in a spatiotemporally defined fashion. 
Some of these DAMPs activate DCs during engulfment, which 
then can prime CD4+ T cells, CD8+ cytotoxic lymphocytes, and 
γδT  lymphocytes against one or several tumor-associated anti-
gens (147).
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